Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus
Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.
You may also be interested in...
Cancer Moonshot Round 2 Focuses On Screening; Pharma To Participate In New Summit
The initial moonshot aimed to increase cancer research while the reboot seeks to boost screenings to reduce death rate. New cancer cabinet mirrors previous task force. Biopharmaceutical companies are to participate in summit to highlight new commitments.
Cancer Moonshot To Tackle Hereditary Colon Cancer Screening
One of the recent recommendations for a Cancer Moonshot demonstration program is to implement genetic testing on a wider scale in family members of people with colon cancer-associated genetic mutations. But with greater visibility, how should the testing paradigm change?
FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'
Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.